חוב כולל להון VolitionRx Limited (VNRX)

VolitionRx Limited (VNRX) develops affordable blood analysis systems for the early detection of oncology. Serving as the primary assessment tool, this price chart demonstrates a metric at 0.00. The company is expanding its Nu.Q platform by implementing panels for veterinary use and screening. However, costly research, slow physician adoption of methodologies, and potential revisions to insurance reimbursements could undermine financial stability.

This indicator is calculated as the ratio of total debt obligations to equity, determining the degree of financial leverage and the business's dependence on borrowed capital. By analyzing the current total liabilities-to-equity ratio of 0.00, an investor can see the stability of VolitionRx Limited (VNRX), whose cancer diagnostics development in the US and Belgium is shielded from geopolitical risks, minimizing the need for emergency lending.